Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 3Phase 2/3 2Phase 1/2 2Phase NA 1Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Interventional × vosaroxin × Clear all
NCT00246662 2017-03-30

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

Sunesis Pharmaceuticals

Phase 1 Completed
75 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00091585 2007-05-10

Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

Sunesis Pharmaceuticals

Phase 1 Completed
Tumor-Agnostic

Neoplasms

NCT00094159 2007-05-10

Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

Sunesis Pharmaceuticals

Phase 1 Completed
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡